ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Syros Pharmaceuticals Inc

Syros Pharmaceuticals Inc (SYRS)

0.105
0.00
(0.00%)
Cerrado 26 Abril 3:00PM
0.00
0.00
(0.00%)
Fuera de horario: -

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
0.105
Postura de Compra
0.10
Postura de Venta
0.1099
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.065 Rango de 52 semanas 6.9275
Capitalización de Mercado [m]
Precio Anterior
0.105
Precio de Apertura
-
Hora
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
23,512,856
Acciones en circulación
26,832,457
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.02
Beneficio por acción (BPA)
-6.13
turnover
9.94M
Beneficio neto
-164.57M

Acerca de Syros Pharmaceuticals Inc

Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is primarily involved in the segments of the pharmaceutical, biotechnology, and other related markets that address gene control and ... Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is primarily involved in the segments of the pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The Company operates only in the United States. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Syros Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SYRS. The last closing price for Syros Pharmaceuticals was US$0.11. Over the last year, Syros Pharmaceuticals shares have traded in a share price range of US$ 0.065 to US$ 6.9275.

Syros Pharmaceuticals currently has 26,832,457 shares in issue. The market capitalisation of Syros Pharmaceuticals is US$2.82 million. Syros Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.02.

SYRS Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1000.1050.1050.10500CS
4000.1050.1050.10500CS
12-0.072-40.67796610170.1770.29690.065235128560.12592377CS
26-1.965-94.92753623192.073.40.065159836400.18965298CS
52-4.835-97.87449392714.946.92750.06580189640.23124863CS
156-1.135-91.53225806451.248.170.06528926620.39815891CS
260-8.095-98.71951219518.215.64990.06519897021.2140896CS

SYRS - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Syros Pharmaceuticals?
El precio actual de las acciones de Syros Pharmaceuticals es US$ 0.105
¿Cuántas acciones de Syros Pharmaceuticals están en circulación?
Syros Pharmaceuticals tiene 26,832,457 acciones en circulación
¿Cuál es la capitalización de mercado de Syros Pharmaceuticals?
La capitalización de mercado de Syros Pharmaceuticals es USD 2.82M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Syros Pharmaceuticals?
Syros Pharmaceuticals ha negociado en un rango de US$ 0.065 a US$ 6.9275 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Syros Pharmaceuticals?
El ratio precio/beneficio de Syros Pharmaceuticals es -0.02
¿Cuál es el ratio de efectivo a ventas de Syros Pharmaceuticals?
El ratio de efectivo a ventas de Syros Pharmaceuticals es 0.27
¿Cuál es la moneda de reporte de Syros Pharmaceuticals?
Syros Pharmaceuticals presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Syros Pharmaceuticals?
El último ingresos anual de Syros Pharmaceuticals es USD 9.94M
¿Cuál es el último beneficio anual de Syros Pharmaceuticals?
El último beneficio anual de Syros Pharmaceuticals es USD -164.57M
¿Cuál es la dirección registrada de Syros Pharmaceuticals?
La dirección registrada de Syros Pharmaceuticals es CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Syros Pharmaceuticals?
La dirección del sitio web de Syros Pharmaceuticals es www.syros.com
¿En qué sector industrial opera Syros Pharmaceuticals?
Syros Pharmaceuticals opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WWWW International Inc
US$ 0.395
(167.62%)
223.58M
OMEXOdyssey Marine Exploration Inc
US$ 1.4979
(75.79%)
285.65M
RTCBaijiayun Group Ltd
US$ 0.3244
(74.88%)
263.23M
GREEGreenidge Generation Holdings Inc
US$ 1.3197
(53.92%)
5.84M
SXTCChina SXT Pharmaceuticals Inc
US$ 2.28
(44.30%)
38.04M
CGTLCreative Global Technology Holdings Ltd
US$ 1.5197
(-75.09%)
3.88M
TOIIWOncology Institute Inc
US$ 0.1015
(-40.22%)
156.14k
COEPCoeptis Therapeutics Holdings Inc
US$ 7.70
(-38.25%)
716.99k
INTSIntesity Therapeutics Inc
US$ 0.56
(-37.78%)
3.21M
SMMTSummit Therapeutics Inc
US$ 23.47
(-36.05%)
24.67M
GNLNGreenlane Holdings Inc
US$ 0.012699
(-15.34%)
355.22M
AGMHAGM Group Holdings Inc
US$ 0.0477
(22.31%)
340.91M
OMEXOdyssey Marine Exploration Inc
US$ 1.4979
(75.79%)
285.65M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.455
(19.62%)
266.95M
RTCBaijiayun Group Ltd
US$ 0.3244
(74.88%)
263.23M

SYRS Discussion

Ver más
Renee Renee 1 mes hace
SYRS delisted from the Nasdaq to the OTC. ***stock dropped 20% from .13 to .1021 on ~15 million volume.

https://otce.finra.org/otce/dailyList?viewType=Additions
👍️0
Zardiw Zardiw 1 mes hace
Try DDAmanda Stock Screener ............

Z
👍️0
Zardiw Zardiw 1 mes hace
#DDAmanda Chart on $SYRS:



Z
👍️0
glenn1919 glenn1919 1 mes hace
SYRS..................................https://stockcharts.com/h-sc/ui?s=SYRS&p=W&b=5&g=0&id=p86431144783
👍️0
Zardiw Zardiw 2 meses hace
#DDAmanda Video: $SYRS: Gain: +157% #1 Early Alert Stock Finder



Z
👍️0
makinezmoney makinezmoney 2 meses hace
$SYRS: Even after that mention at $0.15................. $0.29

So............ "A" run had taken place........ but............ "Another" run had yet to take place.
You look at the volume and momo.

I saw it and recognized it enough to mention.
Even if you get 50% of the entire run, thats still something to relish.
No one calls a perfect bottom or top but the fact that you were able to cash in on some aspect of it is
worth being grateful for.

Only advice is watch the volume bars, check the sentiment, look at if there is a reversal in interest and if news supports
enough to possibly revisit previous valuation levels barring anything that would impede it.

Did you see $PSTV ?
I saw it at $0.60 but that wasnt the bottom, it was $0.30.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175893769
Still ran over $2 !
Thats still a net gainer from when I witnessed it ......... keep your eyes peeled for opportunities.
They always show up somewhere somehow


Your welcome

GO $SYRS
👍️0
JerBear84 JerBear84 2 meses hace
Brand new to Ihub, and investing for that matter. I see your posts often, but after a run has taken place. Do you make alerts or offer any advice as to find a stock before a jump? Thank you.
👍️0
makinezmoney makinezmoney 2 meses hace
$SYRS: $0.20 incoming....................


Nice fire here............. getting hotter still


GO $SYRS
👍️0
makinezmoney makinezmoney 2 meses hace
$SYRS: Nice run here in PM......... now $0.15

wow.......... ran from $0.08

GO $SYRS
👍️0
glenn1919 glenn1919 2 meses hace
SYRS...........................................................................p/m
👍️0
splintered sunlight splintered sunlight 2 meses hace
Thanks

Nice big ole fat juicy tax loss.....................
👍️0
getmoreshares getmoreshares 2 meses hace
caught my eye-- its done-- sell if you have any shares-IMO ACON also had a huge dip yesterday- trading it again today
👍️0
splintered sunlight splintered sunlight 2 meses hace
One of my biggest losers.........
👍️0
getmoreshares getmoreshares 2 meses hace
The Company intends to file a Form 25 with the Securities and Exchange Commission ("SEC") to effect the delisting and deregistration of its common stock on or about March 10, 2025 and the delisting is expected to become effective on or about March 20, 2025.
👍️0
TheFinalCD TheFinalCD 2 meses hace
https://ih.advfn.com/stock-market/NASDAQ/syros-pharmaceuticals-SYRS/stock-news/95562695/form-8-k-current-report
👍️0
bigtalan bigtalan 3 meses hace
What is next for the company anyones input would be great GLTA
👍️0
glenn1919 glenn1919 4 meses hace
syrs..............https://stockcharts.com/h-sc/ui?s=syrs&p=W&b=5&g=0&id=p86431144783
👍️0
The Night Stalker The Night Stalker 5 meses hace
nice
👍️0
glenn1919 glenn1919 5 meses hace
SYRS.................https://stockcharts.com/h-sc/ui?s=SYRS&p=W&b=5&g=0&id=p86431144783
👍️0
ErnieBilco ErnieBilco 5 meses hace
Jumped in on the failed trial 87% down is a decent entry point IMO
👍️0
gail gail 7 meses hace
hopped out for a little profit, to fishy.
👍️0
gail gail 7 meses hace
strong after hours
👍️0
gail gail 7 meses hace
here we goooo!!
👍️0
gail gail 7 meses hace
moving up now.
👍️0
glenn1919 glenn1919 7 meses hace
SYRS........................https://stockcharts.com/h-sc/ui?s=SYRS&p=W&b=5&g=0&id=p86431144783
👍️0
gail gail 7 meses hace
should have waited, lol
👍️0
gail gail 7 meses hace
grabbed some today.
👍️0
splintered sunlight splintered sunlight 8 meses hace
Gee that was easy..........
👍️0
Monksdream Monksdream 8 meses hace
SYRS under $2
👍️0
Monksdream Monksdream 12 meses hace
SYRS under $10
👍️0
chemist72 chemist72 2 años hace
Syros Pharmaceuticals (SYRS) Stock Forecast & Price Target
Follow - 643 Followers
Moderate Buy - 2
Buy - 2
Hold - 0
Sell - 0
Based on 2 analysts giving stock ratings to Syros Pharmaceuticals in the past 3 months
SYRS Stock 12 Months Forecast - $15.00 ?(337.32% Upside) https://www.tipranks.com/stocks/syrs/forecast
👍️0
Mr. Money$ Mr. Money$ 2 años hace
$SYRS: Stock moves quickly on low volume. Large healthcare funds are holding positions
👍️0
Mr. Money$ Mr. Money$ 2 años hace
$SYRS: Does anyone have any information on Syros Pharma? Word on the street says they filed an S3 prior to announcing big news. Your thoughts? The stock seems to move quickly on low volume. Should I hold or sell? Thanks
👍️0
splintered sunlight splintered sunlight 2 años hace
Brookline Capital Markets remains a Buy on SYRS with a $60 Price Target.

Spread the word.
👍️0
splintered sunlight splintered sunlight 3 años hace
Then lets hope for 2...
👍️0
OCEANIC 815 OCEANIC 815 3 años hace
TD Ameritrade has SYRS Short % of float is 130%. If just one drug pans out - major short squeeze. No idea of that will happen but having a little in it is worth it.
👍️0
INFINITI INFINITI 3 años hace
Don’t see it happening
👍️0
knrorrel knrorrel 3 años hace
SYRS come dollar a/h ? weeeé
SYRS moving up WOWZAAAA

SYRS come dollar a/h ? weeeé

https://www.nasdaq.com/market-activity/stocks/syrs/real-time


👍️0
INFINITI INFINITI 3 años hace
Let’s break that dollar and open @ $50
👍️0
PennyPusher786 PennyPusher786 3 años hace
This one is bound to pop to 1+ again... yesterday i loaded .70s mid day and was about to get out srouns 1.08, but watched it touch 1.16 or so.... analysts all calling anywhere from $4-$19 on this one.
👍️0
INFINITI INFINITI 3 años hace
Awesome NEWS!!!!
👍️0
INFINITI INFINITI 3 años hace
Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer

Source: Business Wire
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SY-5609 for the treatment of pancreatic cancer. SY-5609, a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, is currently being evaluated in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer.

“This orphan drug designation underscores the urgency of our efforts to develop SY-5609 for patients with pancreatic cancer, one of the most devastating and difficult to treat malignancies,” said David A. Roth, M.D., Chief Medical Officer of Syros. “Based on the early data we reported last year, which demonstrated single-agent activity in heavily pre-treated patients, as well as compelling preclinical data and a strong mechanistic rationale, we believe SY-5609 could deliver meaningful benefit to people with pancreatic cancer, whose tumors have otherwise eluded therapeutic intervention. We look forward to sharing initial data from the safety lead-in portion of our ongoing Phase 1 study later this year.”

The FDA's Office of Orphan Drug Products grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States. Orphan drug designation may provide certain benefits, including a seven-year period of market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees.

Syros’ ongoing Phase 1 trial is evaluating SY-5609 in combination with chemotherapy in pancreatic cancer patients who have progressed following treatment with FOLFIRINOX. Patients were randomized to receive either SY-5609 in combination with gemcitabine, or SY-5609 in combination with gemcitabine and nab-paclitaxel, at the approved doses of the combination agents. The study is assessing safety and tolerability, as well as efficacy measures such as disease control rate and progression free survival. Safety and clinical activity data from the safety lead-in portion of the trial are expected in the second half of 2022.

Under an existing clinical supply agreement with Roche, Syros is also supplying SY-5609 for a combination dosing cohort in Roche’s ongoing Phase 1/1b INTRINSIC trial. This cohort is evaluating the combination of SY-5609 and atezolizumab in patients with BRAF-mutant colorectal cancer. Roche is the sponsor of the INTRINSIC trial.

About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARa agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding Syros’ clinical development plans with respect to SY-5609, the potential of SY-5609 to deliver meaningful benefit to people with pancreatic cancer, the timing of anticipated data readouts and potential regulatory submissions from Syros’ clinical trials, and the potential for Syros’s product candidates to obtain regulatory approval. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including Syros’ ability to: advance the development of its programs, including tamibarotene, under the timelines it projects in current and future clinical trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; sustain the response rates and durability of response seen to date with its drug candidates; successfully develop a companion diagnostic test to identify patients with the RARA biomarker; obtain and maintain patent protection for its drug candidates and the freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into and maintain collaboration agreements with third parties; manage competition; manage expenses; raise the substantial additional capital needed to achieve its business objectives; attract and retain qualified personnel; and successfully execute on its business strategies; risks described under the caption “Risk Factors” in Syros’ Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, each of which is on file with the Securities and Exchange Commission; and risks described in other filings that Syros makes with the Securities and Exchange Commission in the future. In addition, the extent to which the COVID-19 pandemic continues to impact Syros’ workforce and its clinical trial operations activities, and the operations of the third parties on which Syros relies, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the pandemic, additional or modified government actions, and the actions that may be required to contain the virus or treat its impact. Any forward-looking statements contained in this press release speak only as of the date hereof, and Syros expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.


View source version on businesswire.com: https://www.businesswire.com/news/home/20220913006229/en/

Media:
Brittany Leigh, Ph.D.
👍️0
Expensivetaste281 Expensivetaste281 3 años hace
Thanks
👍️0
PennyPusher786 PennyPusher786 3 años hace
Lol.... They wanna load the boat before it runs for those analyst targets
👍️0
Expensivetaste281 Expensivetaste281 3 años hace
Why
👍️0
PennyPusher786 PennyPusher786 3 años hace
Dark Pool Trades dumping on the run
👍️0
PennyPusher786 PennyPusher786 3 años hace
Wooooohooo, got in just in time, 15 minutes ago! Thanks to After Hours trading. Gluck to all!
👍️0
cardvic cardvic 3 años hace
My advice is sell as soon as possible.
👍️0
mcsharkey mcsharkey 3 años hace
On the Merger with TYME Pharma coming soon.
Annual shareholders' meeting and proxy vote ALWAYS IN August. Syros already had thei=s in June. About 1 .onth before the Merger announcement.

We ALL have to vote on it as a matter of course. The major holders already registered as being compliant with Boards of Directors.

From TYME Investor Relations today: "The meeting details will be disclosed within the next week or so."

After initial & minor PPS SURGE by SYRS on announcement, we've both stagnated.

My opinion? We'll have a joint meeting with merger consumated during it.

One big, happy family.
👍️0
splintered sunlight splintered sunlight 3 años hace
Hopefully $5!!!
👍️0

Su Consulta Reciente

Delayed Upgrade Clock